The primary pathophysiology factors that predispose any patient to VTE are the Virchow's Triad: endothelial injury, venous stasis (or turbulent blood flow), and hypercoagulability. Endothelial injury can occur due to manipulation, and retractor placement during surgery. Venous stasis can occur due to positioning and the use of a tourniquet. Hypercoagulability can occur as a result of depletion or dilution of endogenous anticoagulants. It is also associated with several pro-coagulant disease processes such as factor V Leiden deficiency, protein C and S deficiency, and others.
Natural history
The natural history of venous thromboembolism is variable. There are four potential outcomes when thrombosis occurs. The thrombus can propagate, embolize, organize, or undergo fibrinolysis. Proximal thrombi are more likely to propagate and embolize than the smaller distal thrombi in general. 80% of symptomatic DVTs involve the proximal veins (Conduah & Lieberman, 2007) .
Prevention
Clinical VTEs occur due to many different causes, but one significant factor is inadequate prophylaxis (Amin et al., 2010) . Several barriers exist for inadequate prophylaxis. These include: expense, bleeding concerns, availability of agents, and conflicting recommendations. The American College of Chest Physicians (ACCP) and the American Controversies exist regarding the two major practice guidelines for VTE prophylaxis. The ACCP has been updating its recommendations every 3 years for over 25 years . The AAOS guidelines have been a more recent development. Though the two have many similarities, there are a few significant differences. A major area of disagreement involves the use of DVT as a surrogate for PE in arthroplasty patients. The AAOS guidelines do not emphasize the correlation between DVT and pulmonary embolism (Eikelboom et al., 2009) . In fact, the AAOS guidelines are for the prevention of PE following joint arthroplasty. The ACCP recommendations focus on the prevention of both VTE and PE as the goal rather than PE alone in the AAOS guidelines. Both guidelines focus on a balance between the risk of bleeding and the efficacy of anticoagulation. They both define risk-to-benefit ratio for different agents. Some of the most clinically relevant differences between the two guidelines are presented in Table 1 . Neither guideline has been universally accepted. A recent survey was conducted by the American Association of Hip and Knee Surgeons regarding the practice standards among its member surgeons. The data demonstrated that 74% of the hospitals had adopted the ACCP guidelines, while 68% of the surgeons preferred the AAOS guidelines (Markel et al., 2010) .
Furthermore, compliance with the current guidelines has been suboptimal. Many surgeons continue to under-appreciate the prevalence of VTE and remain concerned with postoperative bleeding. Additionally, patient factors can inhibit appropriate prophylactic treatment. Injectable agents are expensive. Moreover, some patients are not at ease or in compliance with their administration. Oral agents have the challenges including: titration, monitoring, and drug-drug, or drug-food interaction (Moyer et al., 2009 ).
Extended duration prophylaxis
The ACCP guidelines recommend the optimal duration of VTE prophylaxis to be 28 to 35 days following THAs, and 10 to 14 days following TKAs (Kolb et al., 2003) . Currently, the mean length of hospital stay is between 3 to 4 days, therefore full compliance with this recommendation is difficult for both the patient and the provider. Several studies have reported that continuation of thromboprophylaxis beyond the hospitalization is efficacious and safe in the risk reduction of late VTE in surgical patients (Planes et al., 1996; Lassen et al., 1998; Comp et al., 2001; Bergqvist et al., 2002; Rasmussen et al., 2006) .
Extended duration prophylaxis for VTE requires proper selection of pharmacological agent(s). The ideal anticoagulant should have the following characteristics: standard dosing with self-administration, no requirement for monitoring, established efficacy and safety profiles, acceptable tolerability in populations with co-morbid conditions, and few drugdrug or drug-foot interactions. The ACCP guidelines currently recommend warfarin, lowmolecular weight heparins (LWMH), and fondaparinux. They specifically recommend against using aspirin alone in the high-risk orthopedic patient population as there are insufficient evidence-based data.
The AAOS guidelines recommend 2 to 6 weeks of prophylaxis with warfarin, 6 weeks using aspirin, or 7 to 12 days using LMWH or fondaparinux (AAOS 2007 2011;22:193-197.) 
Quality measures
Over the past 5 years, quality measures have been proposed and put into clinical application to monitor compliance with best practice guidelines in VTE prophylaxis. The Surgical Care Improvement Project (SCIP) was created in 2006 with reduction of VTE being one of its four primary focus areas. The Center for Medicare and Medicaid Services (CMS) has declared postoperative VTE as a "never event." As such, the CMS will no longer reimburse the hospital the costs associated with these complications. Other agencies and consumer groups have also declared VTE as a preventable complication.
Several important improvements have already occurred as a result of these outcome measures. Surgeons and administrators have collectively established hospital-wide or hospital system-wide prophylaxis protocols. They have also worked to establish training and education programs to deliver the best practice guidelines to all the staff involved in patient care. Several limitations still exist however. The AAOS and the ACCP guidelines should be modified to establish a consensus. Unmet needs and improvement in the safety profiles hopefully will be fulfilled by newer agents in clinical development (Huo, 2011a) .
Specific modalities
A summary of specific oral pharmacologic agents currently in clinical application for orthopedic patients is in Table 2 . 
Mechanical
Mechanical prophylaxis using sequential compressive devices (SCDs) or foot pumps can be used as a sole means of VTE prophylaxis. Their clinical efficacy and safety have been documented in multiple studies. This is particularly useful in a patient that is perceived to have an elevated bleeding risk (Geerts et al., 2008) . In many practices, mechanical devices are often used in conjunction with pharmacological prophylaxis. Newer devices may be used in the outpatient setting upon hospital discharge. The clinical efficacy, safety, and compliance have been documented in a few studies. It is necessary to continue to follow larger cohorts of patients using outpatient mechanical prophylaxis alone to fully determine the efficacy and compliance.
Warfarin
Warfarin has been used as VTE chemoprophylaxis in high-risk orthopedic patients for decades. It is an efficacious agent. However, it requires close monitoring. It can be both difficult and costly in the outpatient setting (Eikelboom & Weitz, 2007) . It also has numerous drug-drug and drug-food interactions. These interactions can be particularly challenging considering the issue of poly-pharmacy in the elderly joint arthroplasty patient population. It also has a delayed onset of action, which may require bridging with a shorter acting anticoagulant such as LMWHs or unfractionated heparin. A recent paper by Caprini et al. noted that physicians often used inadequate bridging protocols in the postoperative period. This can have important clinical implications. They found that the 30-day mortality rate was found to be 6% for DVT and 12% for PE in this cohort (Caprini et al., 2005) .
Aspirin
The ACCP guidelines do not recommend using aspirin alone in any of the high-risk orthopedic patient populations. The AAOS guidelines do sanction its use in patients with standard risk profile for pulmonary embolism prevention (Geerts et al., 2008) .
Unfractionated heparin
This has been included in the ACCP guidelines for patients undergoing general surgery procedures. However, the ACCP guidelines have recommended against using unfractionated heparin alone in total joint arthroplasty or hip fracture patients due to inadequate evidence-based data to support its efficacy in these patient populations (Geerts et al., 2008) .
Low-molecular-weight heparin
In contrast to warfarin, LMWHs have a predictable dose response with few interactions. Self-administration is generally well-tolerated and acceptable patient compliance has been documented in several studies. Additionally, there is no need for monitoring (Noble & Finlay, 2005) . Dose adjustment may be necessary in the elderly, in particular in those with compromised renal clearance. LMWHs have considered to be the standard-of-care in many medical communities (Geerts et al., 2008) .
Newer agents
There are several new oral anticoagulants in various stages of clinical development. These new classes target the inhibition of either thrombin or factor Xa. Most of the clinical trial data have demonstrated equal or even superior efficacy in comparison to LMWH. However, bleeding complications remain the primary concern. There are several other potential complications that have been reported.
Newer agents of historic importance
Ximelagatran was the first direct-thrombin inhibitor, and was approved initially by the European regulatory agencies. The initial trials showed no signs of liver toxicity in shortterm use of up to 11 days (Eriksson et al., 2003) . However, extended treatment (greater than 35 fays) was found to be associated with an increased risk of liver toxicity in one study (Agnelli et al., 2009 ). The liver toxicity was unpredictable, and the product was later withdrawn from the market (Vaughan, 2005) .
Razaxaban was the first oral Factor Xa inhibitor to be developed. Data from phase I clinical trials demonstrated adequate efficacy and safety (Spyropoulos, 2007) . A phase II trial involving TKA patients demonstrated significantly higher bleeding complication rates when compared with enoxaparin (Lassen et al., 2003) . The trial was terminated prematurely and the drug development was discontinued.
Current oral anticoagulants
Dabaigatran etexilate is a pro-drug of the direct thrombin inhibitor, dabigatran (Eriksson et al., 2004) . There have been four phase III clinical trials comparing this drug to enoxaparin. In addition, a meta-analysis of three of these has been conducted (Wolowacz et al., 2009 ). It demonstrated non-inferiority to once-daily enoxaparin 40mg dose in one clinical trial involving THA, but failed to do so when compared to twice-daily enoxaparin dosing with 30mg Additionally, it demonstrated non-inferiority to once-daily enoxaparin 40mg dose in two clinical trials involving THA patients (Eriksson et al., 2007a; Eriksson et al., 2007b) . It was approved in the European Union and in Canada in 2008 for use in total joint arthroplasty patients as VTE prophylaxis. In the United States, it was approved for use in certain atria fibrillation patients for stroke prevention (Huo, 2011b) .
Rivaroxaban and apixabab are both inhibitors of factor Xa. Their mechanism involves the inhibition of circulating factor Xa as well as bound factor Xa within the prothrombinase complex (Weitz, 2006) . There have been four phase III clinical trials comparing rivaroxaban to enoxaparin (Eriksson et al., 2008) . It also is approved in the European Union and Canada for VTE prophylaxis in patients undergoing THAs and TKAs. It has recently been approved in the United States.
Apixaban has been evaluated in several phase III clinical trials as well. It has not been approved for use anywhere (Lassen et al., 2010a) . It was found to be more efficacious than once-daily dosing of enoxaparin, but failed to demonstrate non-inferiority to twice daily dosing of enoxaparin Lassen et al 2010b) .
Potential problems with the newer agents
Bleeding events are the most important complication. A recent survey reported that 50% or more orthopaedic surgeons in the United States stated that they were more concerned with bleeding than the risk of VTE (Anderson et al., 2009) . Major bleeding has occurred with all of these agents as it has with other pharmacological agents. LMWHs have been studied for over 20 years, and the incidents of significant bleeding complications ranges from 0.9% to 9.3% (Leizorovicz et al., 1992) . A major difference between LMWH and the newer agents is that enoxaparin can be at least partially reversed using protamine in certain situations (Crowther et al., 2002) . The thrombin and factor Xa inhibitors have no such reversal agents yet (Ng & Crowther, 2006 ). An overview of the bleeding in clinical trials involving new agents is included in Table 3 . It is also important to note the effect of drug-drug interactions. There have been trials showing prolonged bleeding when rivaroxaban was taken with clopidogrel or aspirin (Perzborn et al., 2007) . Though there may be a relationship between bleeding and infection, the use of anticoagulation has not specifically been associated with a higher infection rate (Parvizi et al., 2007; Saleh et al., 2002) .
Aside from bleeding risk, there are other adverse effects that have been documented with the thrombin and factor Xa inhibitors. Drug-induced liver toxicity is the most common reason cited for the withdrawal of a drug from the market (Lee, 2003) . The exact mechanism has not been identified. There have been several trials with dabigatran that reported elevated liver enzymes, but all returned to baseline within 2 months (Eriksson et al., 2007b) . Dabigatran is a substrate for the cellular transporter P-glycoprotein which could be a mechanism of drug interaction (Aszalos, 2007) . CYP240 enzymes are involved in the metabolism of both factor Xa inhibitors (Bayer Inc, 2010) . Both factor Xa and thrombin inhibitors are excreted through the renal system, so this could potentially lead to complications.
Both types of drugs are promising alternatives due to several characteristics. They have predictable pharmacokinetics, few drug interactions, and no monitoring is required (Weitz et al., 2008) . It is important to note that a perfect anticoagulant does not exist at this point. The thrombin and facto Xa inhibitors have been shown to be effective and safe in multiple trials, but there still is a lack of data from community practice. 
Conclusion
VTE remains a challenging problem that complicates many orthopaedic procedures. The incidence has been found to be particularly high following TKA and THA. Governmental and consumer governing bodies are beginning to recognize it as a "never-event" indicating that increased emphasis will be placed on prophylaxis in the years to come. Recommendations have been released by both the ACCP and the AAOS and there remains some disagreement as to the optimal management of VTE. Warfarin and LMWH remain the standard of care in many practices, but newer agents show increasing promise.
The authors have several recommendations regarding the duration and type of therapy. Patients should be anticoagulated for 25-30 days postoperatively following total hip arthroplasty and for 14 days following a total knee arthroplasty. Certain patients with high risk of VTE (obese, low mobility, prior VTE, family history of VTE, or protein C/S deficiency) should be treated for 25-30 days as well following hip or knee replacement. At our institution, we generally use enoxaparin for postoperative anticoagulation. For inpatients, either 30mg twice daily or 40mg daily may be used following total hip arthroplasty. The FDA has approved only the twice daily dosing after total knee arthroplasty. For outpatients, enoxaparin 40mg daily is our regimen of choice. 
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